Gene: CCDC171

203238
C9orf93|bA536D16.1|bA778P13.1
coiled-coil domain containing 171
protein-coding
9p22.3
Ensembl:ENSG00000164989 Vega:OTTHUMG00000019584 UniprotKB:Q6TFL3
NG_052634.1
SNP Mapped
0   ANCO-SNPs
AD
0   
3.768e-1 (AD)  6.856e-1 (ND)   (Frontal_Cortex)
5.149e-1 (AD)  4.994e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
DOPEY10.845
TBC1D320.835
ZNF3820.833
ICA1L0.826
ANKRD36C0.824
DTWD20.821
BDP10.82
ANKRD260.813
PPIP5K20.812
CSMD30.801

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CSAG1-0.436
CCDC102A-0.425
SPINK8-0.403
SERTAD1-0.386
RAB13-0.38
PGF-0.37
ROM1-0.369
C7orf61-0.365
MDFI-0.363
CDC42EP5-0.356

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0112692,5-hexanedione"2,5-hexanedione results in increased expression of CCDC171 mRNA"22952946
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC171 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC171 mRNA"27188386
D018501Antirheumatic AgentsAntirheumatic Agents results in decreased expression of CCDC171 mRNA24449571
D001280AtrazineAtrazine results in increased expression of CCDC171 mRNA25929836
D001280AtrazineAtrazine results in decreased expression of CCDC171 mRNA22378314
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of CCDC171 mRNA26238291
C006780bisphenol Abisphenol A results in decreased expression of CCDC171 mRNA25181051
C018475butyraldehydebutyraldehyde results in decreased expression of CCDC171 mRNA26079696
C029892cupric chloridecupric chloride results in decreased expression of CCDC171 mRNA24650576
D002945Cisplatin[Cisplatin co-treated with jinfukang] results in decreased expression of CCDC171 mRNA27392435
D002945CisplatinCisplatin results in decreased expression of CCDC171 mRNA27392435
C039281furanfuran results in increased methylation of CCDC171 gene22079235
C544151jinfukang[Cisplatin co-treated with jinfukang] results in decreased expression of CCDC171 mRNA27392435
D008558MelphalanMelphalan results in decreased expression of CCDC171 mRNA22363485
D008727MethotrexateMethotrexate results in increased expression of CCDC171 mRNA24449571
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of CCDC171 mRNA23103053
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of CCDC171 mRNA28001369
C583365N-(2-(1,1'-bicyclopropyl)-2-ylphenyl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide"N-(2-(1,1'-bicyclopropyl)-2-ylphenyl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide results in increased expression of CCDC171 mRNA"29244179
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in decreased expression of CCDC171 mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of CCDC171 mRNA"25554681
D009532NickelNickel results in decreased expression of CCDC171 mRNA25583101
C046012pentanalpentanal results in decreased expression of CCDC171 mRNA26079696
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC171 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of CCDC171 mRNA26272509
C006253pirinixic acidpirinixic acid results in increased expression of CCDC171 mRNA23811191
D011192Potassium DichromatePotassium Dichromate results in decreased expression of CCDC171 protein23718831
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of CCDC171 mRNA27913140
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of CCDC171 mRNA26377647
D019284ThapsigarginThapsigargin results in decreased expression of CCDC171 mRNA22378314
C012589trichostatin Atrichostatin A results in decreased expression of CCDC171 mRNA24935251
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in increased expression of CCDC171 mRNA"26179874
D014415TunicamycinTunicamycin results in decreased expression of CCDC171 mRNA22378314
D014635Valproic AcidValproic Acid results in decreased methylation of CCDC171 gene29154799
D001335Vehicle EmissionsVehicle Emissions affects the methylation of CCDC171 gene25560391

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO ID GO Term Qualifier Evidence PubMed
GO ID GO Term Qualifier Evidence PubMed
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal